Cold Urticaria: Clinical Trials

10 trials for Cold Urticaria, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

10 completed. 10 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	10	Completed 10
Phase 2	1	Completed 1

Follow Cold Urticaria: new trials by email Literature Review of Cold Urticaria trials Research Report on Cold Urticaria

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS) Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine - Cold Urticaria	Phase 3	Completed	Sanofi	82	2020-12-10	2025-09-10
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies canakinumab - Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers	Phase 3	Completed	Novartis Pharmaceuticals	31	2014-11-03	2020-05-19
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease ACZ885 - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome	Phase 3	Completed	Novartis Pharmaceuticals	17	2012-01-16	2018-09-11
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease ACZ885 - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome	Phase 3	Completed	Novartis Pharmaceuticals	17	2010-11-01	2017-03-29
Bilastine Updosing - Characterization of Underlying Mechanisms Bilastine - Cold Contact Urticaria	Phase 2 / Phase 3	Completed	Charite University, Berlin, Germany	20	2010-09-01	2012-05-31
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada canakinumab (company code: ACZ885D) - Cryopyrin Associated Periodic Syndrome	Phase 3	Completed	Novartis Pharmaceuticals	4	2010-08-01	2017-03-21
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase canakinumab - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome	Phase 3	Completed	Novartis Pharmaceuticals	19	2009-10-01	2020-09-25
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Canakinumab (ACZ885) - Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome	Phase 3	Completed	Novartis	166	2008-05-01	2016-11-04
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome ACZ885, Placebo - Muckle Wells Syndrome	Phase 3	Completed	Novartis	35	2007-04-01	2017-08-28
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) rilonacept 160 mg, Placebo - Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria	Phase 3	Completed	Regeneron Pharmaceuticals	104	2005-12-01	2011-12-06

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding